Physician profile
Vikas Jain
NPI 1558508176
$7,846.49
in general payments reported to CMS, 2019-2025
19 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.31 · 2021: $488 · 2022: $1,434 · 2023: $336 · 2024: $5,272 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $1,091 · Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $1,091.42 |
| Food and Beverage | $813.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,570.36 | 2022-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $216.09 | 2021-2023 | Fasenra |
| Actelion Pharmaceuticals US, INC. | $213.14 | 2021-2022 | |
| Grifols USA, LLC | $121.80 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $113.80 | 2021-2023 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.67 | 2021-2022 | |
| Glaxosmithkline, LLC. | $86.24 | 2021-2025 | Trelegy Ellipta |
| Ucb, INC. | $78.84 | 2022-2023 | Cimzia |
| Abbvie INC. | $57.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.61 | 2021-2025 | Keytruda |
| Olympus America INC. | $41.08 | 2021-2022 | |
| Genzyme Corporation | $35.86 | 2025 | |
| Amgen INC. | $34.84 | 2022-2024 | Tezspire |
| Gilead Sciences, INC. | $31.33 | 2021-2022 | |
| Pulmonx Corporation | $29.96 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $19.62 | 2021 | |
| Advanced Respiratory, INC | $15.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.11 | 2022 | |
| Octapharma USA, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.